Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 15;116(19):9543–9551. doi: 10.1073/pnas.1819745116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published under the PNAS license.

PMC Copyright notice

Fig. 2. — Clinical overall response and survival in R/R MM to CAR T. (A) Duration of response to LCAR-B38M and post-infusion survival in 17 cases. (B and C) Disease clearance upon LCAR-B38M in a representative case (RJ01). (B) Flow cytometry detection of BM MRD before and 2 mo after CAR T. (C) The change of plasma M-protein concentration in RJ01 after CAR T infusion. The latest assessment was on day 413 post CAR T. (D and E) Response to LCAR-B38M in another representative case (RJ04). (D) Flow cytometry detection of BM MRD before and 1 mo after CAR T. (E) The change of plasma M-protein concentration, with the latest assessment at day 365 post CAR T. (F) The curve shows the time to progression after infusion of LCAR-B38M. Tick marks indicate the time of data censoring at the last follow-up. (G) The curve shows overall survival data censored at the time of the last follow-up.